Safety & Efficacy of Nuberol Forte® in Pain Management
Condition: Musculoskeletal Disorder; Pain Management
MeSH terms: Musculoskeletal Diseases
Study type: Observational

Summary: 
      The global prevalence of Musculoskeletal disorders (MSD) ranges from 14% to as high as 42%.
      In addition WHO also estimates that 40% of people over the age of 60 years suffer from MSD
      and about 80% of the people have had low back pain at some point in their life. In Pakistan,
      to estimate the prevalence of MSD, there is no data available based on the local population.
      Locally, studies were conducted on the specific subject pools mainly considering the work
      related musculoskeletal disorders and backache. However, no real data is available for the
      symptomatic management of painful musculoskeletal disorders in multiple settings to calculate
      more generalizable results. So this study is planned and if we found good results then it
      will help physicians to prescribe the above said medicine to all such cases.
    

Detailed description: 
      The management of musculoskeletal pain is complex therefore plethora of treatment options are
      available include non-pharmacological treatments , complementary therapies, and
      pharmacological interventions. In order to provide optimal care to patients with
      musculoskeletal pain and ensure the efficient use of healthcare resources, a comprehensive
      overview of the available evidence for the most effective treatment options for
      musculoskeletal pain presentations is essential. In this context, an observational study is
      planned on the efficacy and safety of analgesic combination (i.e Nuberol Forte®). Nuberol
      Forte® is a combination of muscle relaxant (Orphanedrine) and an analgesic/antipyretic
      (Paracetamol/Acetaminophen). There are clear indications that the combination of Orphenadrine
      with Paracetamol may give increased antinociceptive activity and duration of action over and
      above the use of Orphenadrine or Paracetamol alone.
    

Intervention name(s): Combination of Paracetamol 650mg + Orphenadrine 50mg
Intervention type(s): Drug
Intervention description(s): In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
Other intervention name(s): Nuberol Forte
Intervention MeSH terms: Acetaminophen; Orphenadrine
Observational model: Cohort
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        Pakistani patients suffering from painful musculoskeletal disorders includes ankle and knee
        sprains, non-articular low-back pain, painful shoulder lesions (rotator cuff syndrome) and
        a variety of occupational and sport injuries of the soft tissues in random order. In each
        case, subjective measures of pain, muscle spasm, stiffness and other symptoms of the
        musculoskeletal pain will be assessed through Muscle & Joint Measure Scale (MJM). The
        possible side-effects will be recorded along with other data.The physician will recruit the
        musculoskeletal patients as per standard practice based on the medical judgment and after
        review of subject's medical history, results of routine screening, physical and general
        examination.
      
Keywords: Musculoskeletal Disorder, Nuberol Forte, Pakistan